Drug payment proposal would slash pay to ASP + 4% in 2008

Article Overview

This article explains a proposed Medicare budget change affecting Part B drug reimbursement and why the issue matters for oncology practices, cancer centers, and other stakeholders in physician-administered drug payment policy. It places the proposal in the context of federal budgeting and Medicare spending, and includes a comparison table showing how selected cancer drug payments would differ under two pricing approaches. The piece is relevant to billing, reimbursement, and practice management professionals tracking Medicare policy changes.